BioCentury
ARTICLE | Company News

Transkaryotic, Aventis deal

December 11, 2000 8:00 AM UTC

TKTX reacquired from AVE worldwide commercial rights to GA-II, an undisclosed protein developed using TKTX's gene activation technology. TKTX said the reacquisition was a joint decision of the compani...